Perspective Therapeutics, Inc. CATX
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Perspective Therapeutics, Inc. (CATX) is a healthcare company listed in the US with a market value of about $114M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -31%.
About Perspective Therapeutics
Perspective Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $5M in 2015 to $1M in 2023, a decline of about 13.6% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 420% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $1M | $0 | $10M | $10M | $7M | $6M | $5M | $5M |
| Net income | -$103M | -$79M | -$47M | -$11M | -$3M | -$3M | -$5M | -$7M | -$6M | -$5M |
| Free cash flow | -$95M | -$73M | -$38M | -$11M | -$3M | -$4M | -$5M | -$6M | -$6M | -$4M |
| EPS (diluted) | $-1.40 | $-1.23 | $-1.74 | $-0.80 | $-0.30 | $-0.50 | $-0.80 | $-1.20 | $-1.10 | $-0.90 |
| Net margin | — | — | -3243.2% | — | -33.7% | -35.6% | -70.3% | -113.1% | -129.4% | -98.8% |
| ROIC | -53.6% | -30.0% | -49.2% | -15.8% | -4.0% | -40.8% | -54.0% | -105.7% | -47.0% | -24.5% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Perspective Therapeutics pay a dividend?
Not currently.
Is Perspective Therapeutics a good stock to buy?
We do not give buy or sell advice. Perspective Therapeutics scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.